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The large-scale production of cardiomyocytes is a key step in the development of cell therapy and tissue engineering to treat
cardiovascular diseases, particularly those caused by ischemia. The main objective of this study was to establish a procedure
for the efficient production of cardiomyocytes by reprogramming mesenchymal stem cells from adipose tissue. First, lentiviral
vectors expressing neoR and GFP under the control of promoters expressed specifically during cardiomyogenesis were constructed
to monitor cell reprogramming into precardiomyocytes and to select cells for amplification and characterization. Cellular
reprogramming was performed using 5󸀠-azacytidine followed by electroporation with plasmid pOKS2a, which expressed Oct4,
Sox2, and Klf4. Under these conditions, GFP expression began only after transfection with pOKS2a, and less than 0.015% of
cells were GFP+. These GFP+ cells were selected for G418 resistance to find molecular markers of cardiomyocytes by RT-PCR
and immunocytochemistry. Both genetic and protein markers of cardiomyocytes were present in the selected cells, with some
variations among them. Cell doubling time did not change after selection. Together, these results indicate that enrichment with
vectors expressingGFP and neoRunder cardiomyocyte-specific promoters can produce large numbers of cardiomyocyte precursors
(CMPs), which can then be differentiated terminally for cell therapy and tissue engineering.
1. Introduction
Cardiovascular diseases are the number one cause of death
worldwide. In 2008, approximately 17.3 million people died
from cardiovascular diseases, representing 30% of global
deaths [1]. Cardiac muscle tissue lost by ischemia is replaced
by scar tissue, which overloads cardiovascular activity and
can lead to heart failure in the long term [2].Thedevelopment
of newdrugs, equipment, and surgical techniques has amelio-
rated these cardiac symptoms, but the risk of death associated
with heart failure is still high, and long-term treatments cause
high economic impact [3].
One way to circumvent this pathological progression is to
replace the damaged tissue with functional tissue. This task
can be performed by transplanting in loco cardiomyocytes
or cardiomyocyte stem cells or precursor cells. If the injured
area is too large, then these cells can be placed in a scaffold
and transplanted into the heart after removal of fibrous tissue
[3, 4]. However, to perform these processes, a large amount of
the patient’s cardiomyocytes is necessary, which is one of the
main challenges today. In theory, these cells can be obtained
from adult stem cells residing in the heart, but there are
technical difficulties in obtaining them in sufficient amounts.
For example, cardiac biopsy from a sick heart is a highly risky
procedure [5].
On the other hand, embryonic stem cells (ESCs) seem
to be a good source of functional cardiomyocytes [6]; how-
ever, several biological issues related to teratoma formation,
immunological rejection, and chromosomal instability, as
well as the ethical issue of the source of ESCs, are highly
concerning [7]. Induced pluripotent stem cells [8] can over-
come the ethical issue, but the concerns related to the ESC
properties remain.
Mesenchymal stem cells (MSCs) have emerged as an
alternative source of cardiomyocytes and other cell types
because these cells can be obtained in large amounts from
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adult fat tissue and bone marrow [9, 10]. However, several
methods of cell differentiation have led to a small percentage
of cardiomyocyte-like cells fromMSCs. It is important to note
that, in these papers, the authors characterized the differenti-
ated cardiomyocytes with a small number of cardiomyocyte
markers by immunocytochemistry and/or RT-PCR, which
cannot represent true cardiomyocytes [11–15]. Additional
analyses, such as electrophysiology, will be necessary to
validate these cells.
There are at least three critical issues to be considered
in order to produce cardiomyocytes on a large scale using
stem cells: the efficiency of differentiation in cardiomyocytes
is relatively low [16], these differentiated cells have variable
phenotypes [12, 14], and the expansion of cardiomyocytes is
difficult because mature cardiomyocytes are senescent [17].
These issues can be overcome if the MSCs that are destined
to differentiate into cardiomyocytes can be identified and
selected before differentiating terminally into cardiomy-
ocytes, as these selected precardiomyocytes, or cardiomy-
ocyte precursors (CMPs), should bemore homogeneous than
terminally differentiated cardiomyocytes and should possess
the capacity to divide.
In this study, we describe a method of enrichment of
CMPs from MSCs to facilitate cell multiplication and differ-
entiation into cardiomyocytes later. This approach is based
on the use of vectors with cardiomyocyte-specific gene
promoters, such as ATP2A2, GJA1, and NPPA, to direct the
expression of neoR and GFP in MSC cultures undergoing
differentiation into cardiomyocytes.
The ATP2A2 gene encodes for SERCA2a protein
(NG 007097.2), a sarcoplasmic ATPase involved in the
regulation of contraction and relaxation cycle. This gene is
activated at the heart chambers during heart development
and is expressed over adult life [18].
TheGJA1 gene encodes for connexin 43 (NG 008308.1), a
gap junction protein that is necessary for electrical coupling
of cardiomyocytes. The GJA1 expression starts early in the
embryonic development and is present in adult organs [19].
The NPPA gene encodes for natriuretic peptide A
(NG 012926.1), a protein implicated in the control of extracel-
lular fluid volume and electrolyte homeostasis. Its expression
starts at linear heart tube formation, thus before GJA1 expres-
sion but earlier than ATP2A2 expression. The expression of
NPPA is related to the maturation of cardiomyocytes and its
expression in adult phase occurs only at cardiac atria [20].
The use of different promoters allows for the selection
of cells at different stages of cardiomyocyte differentiation,
which can then be compared with respect to their efficiency
of proliferation, ability to differentiate into cardiomyocytes,
and cell quality.
2. Materials and Methods
2.1. Construction of Lentivectors with Cardiomyocyte-Specific
Promoters. The neoR cDNA was excised from the pDsRed-
Monomer-C1 vector (Clontech, Mountain View, CA, USA)
with AvrII (all restriction enzymes were purchased from
NEB, Ipswich, MA, USA, and Fermentas, Hanover, MD,
USA), treated with Klenow polymerase (NEB), and inserted
into the SmaI site of pIRES2-EGFP (Clontech). This final
vector was named pNeoR-IRES2-EGFP.
The ATP2A2 promoter (585 bp) was obtained by the
digestion of the vector pGL2SER-263 ([21]; kindly provided
by Dr. Kenneth R. Boheler, NIH, USA) with the restriction
enzymes KpnI and XbaI. The fragment ATP2A2 was treated
with Klenow and inserted at the SmaI site of the pBSK
plasmid (Stratagene, La Jolla, CA, USA). pBSK-ATP2A2 and
pNeoR-IRES2-EGFP were digested with EcoRI and BamHI
and ligated.The product of the last reaction was digested with
NheI and BsrGI to obtain the ATP2A2-neoR-IRES2-EGFP
cassette; this cassette was then inserted into the lentiviral
vector pLL3.7 [22], which was previously digested with XbaI
and BsrGI. The final vector was named pLL-ANG.
The GJA1 (503 bp) and NPPA promoters (577 bp)
were amplified by PCR from human genomic DNA from
HEK293T cells using the following primers (Integrated
DNA Technologies, Coralville, IA, USA): GJA1p Forward
5󸀠-TTGAATTCTGGTTATATGCTTCCCCACC,
GJA1p Reverse 5󸀠-AAGTCGACAAGTGATTGAACTCCT-
TGGAGG, NPPAp Forward 5󸀠-TTGAATTCATGAGG-
CAGGTGTGAGGC, and NPPAp Reverse 5󸀠-TTGTCGA-
CCCACTGCTTGCTGCTCTG. These primers were
designed based on data from the literature [23–26], and
EcoRI and SalI sites were included in the forward and reverse
primers, respectively.The amplification conditions were 95∘C
for 3min followed by 35 cycles of 95∘C for 30 s, 52∘C (GJA1)
or 55∘C (NPPA) for 60 s, and 72∘C for 60 s, and finally 72∘C
for 7min (Mastercycler Gradient 5341, Eppendorf, Hamburg,
Germany). The DNA fragments containing the promoter
sequences were digested with EcoRI and SalI and inserted
into pNeoR-IRES2-EGFP, which was previously digested
with the same enzymes. The GJA1-neoR-IRES2-EGFP and
NPPA-neoR-IRES2-EGFP cassettes were excised with XhoI
and BsrGI enzymes and inserted into the lentiviral vector
pLL3.7 [22], which was previously digested with the same
enzymes. The final vectors were named pLL-GNG and
pLL-NNG, which contained the GJA1 and NPPA promoters,
respectively.
A control vector containing the CMV promoter was
also constructed by the ligation of pNeoR-IRES2-EGFP and
pLL3.7 vectors digested withNheI and BsrGI.This vector was
named pLL-CNG. All final vectors were analyzed by DNA
sequencing.
2.2. Cell Culture. The cell lineages HEK293T (human embry-
onic kidney cell line) [27], NIH3T3 (murine fibroblast cell
line) [28], and H9C2 (rat cardiomyoblast cell line) [29]
were maintained in Dulbecco’s Modified Eagle Medium
(DMEM, GIBCO, Auckland, New Zealand) supplemented
with 10% fetal bovine serum (FBS, GIBCO), 0.2mM
glutamine (Glutamax-1, GIBCO), 10U/mL penicillin, and
10 𝜇g/mL streptomycin (GIBCO).Thehuman endothelial cell
line ECV304 [30] was maintained in DMEM/F12 medium
(Cultilab, Campinas, SP, Brazil) supplemented with 10% FBS,
0.2mM glutamine (Glutamax-1, GIBCO), 10U/mL peni-
cillin, and 10 𝜇g/mL streptomycin (GIBCO).
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Mesenchymal stem cells from adipose tissue (ADSCs)
were isolated from human lipoaspirate samples according to
Zuk et al. [31]. Briefly, these cells were washed extensively
with PBS (137mM NaCl, 2.7mM KCl, 10mM Na
2
HPO
4
,
and 2mM KH
2
PO
4
; pH 7.4) and incubated with 1mg/mL
collagenase type I at 37∘C for 10 minutes. Collagenase was
neutralized by addition of Minimum Essential Medium
(𝛼-MEM, GIBCO) supplemented with 10% FBS, 0.2mM
glutamine, 10U penicillin, and 10𝜇g streptomycin. The cells
were centrifuged at 800×g for 10 minutes. The precipitated
cells were suspended at a concentration of 2 × 106 cells/mL
in 𝛼-MEM supplemented with 10% FBS, 0.2mM glutamine,
10U/mL penicillin, and 10 𝜇g/mL streptomycin. The cells
were maintained in this medium, which was replaced with
fresh medium every 2 to 3 days.
2.3. Viral Production and Titration. Viral vectors were pro-
duced following a method described by Barde et al. [32].
Briefly, 2 × 106HEK293T cells were plated on each 10 cm2
plate containing DMEM with 10% FBS, 0.2mM glutamine,
10U penicillin, and 10 𝜇g streptomycin. Four 10 cm2 plates
were used to produce each batch of viral vector. One day after
plating, the medium was replaced with fresh medium, and
20𝜇g of transfer vector, 5𝜇g pRSV-REV, 10 𝜇g pMDLg/pRRE,
and 6 𝜇g pCi-VSVG were used to transfect each plate of
HEK293T cells by the calcium phosphate coprecipitation
method. The culture supernatant was collected after 24
and 48 hours, filtered using a 0.45𝜇m syringe (Millex HV
0.45 𝜇m, Millipore, Massachusetts, USA), and concentrated
by centrifugation at 14,000 rpm at 4∘C for 2 hours in a
sucrose gradient (Sorvall RC 5C Plus, SA600 rotor, Thermo
Scientific, North Carolina, USA).The concentrated materials
were stored at −80∘C until use.
pLL-CNG virus was titrated based on the method
described by Barde et al. [32]. In a 24-well plate, 2 × 104
HEK293T cells were plated in DMEMwith 10% FBS, 0.2mM
glutamine, 10U penicillin, and 10 𝜇g streptomycin. After 24
hours, various concentrations of virus were added to each
well in the presence of 8 𝜇g/mL Polybrene (Sigma-Aldrich,
Milwaukee, USA). After 48 hours, the cells were analyzed by
fluorescence microscopy (IX70 inverted microscope, Olym-
pus, Tokyo, Japan). This experiment was repeated at least
three times, and the titer was calculated by the mean of the
titers plotted in the linear phase of the graph according to the
following equation:
Titer (TU/mL)
=
%GFPpositive cells × total number of cells
virus volume (mL)
,
(1)
TU: transduction units.
2.4. Validation of Cardiomyocyte-Specific Promoters. To val-
idate the cardiomyocyte specificity of the ATP2A2, GJA1,
andNPPA promoters, H9C2, HEK293T, NIH3T3, and ADSC
cells were transduced with the lentivectors constructed in
Section 2.1 and shown in Figure 1. For the transduction of
ADSC and H9C2 cells, 4 × 104 cells were plated per well in
a 6-well plate; for HEK293T and NIH3T3 cells, 2 × 104 cells
were plated per well in a 24-well plate. The next day, the
mediumwas replacedwith freshmediumcontaining 8𝜇g/mL
Polybrene, and 10 𝜇L of viral solution was added.
The expression of GFP was monitored for 9 days using
an IX70 inverted fluorescence microscope (Olympus). The
transduced cells were selected by adding 1mg/mL G418
(Invitrogen, Carlsbad, CA, USA) to the medium, which was
replaced with fresh medium containing 1mg/mL G418 every
2 to 3 days for 10 days. The selected cells were plated on
coverslips placed in 24-well plates at 1 × 103 cells per well
and cultured using the same cell culture conditions described
previously. After 24 hours, the medium was siphoned off
carefully, the cells were fixed with 4% paraformaldehyde,
and epifluorescence images were acquired for analysis (BX51
fluorescent microscope, Olympus).
2.5. Reprogramming, Selection, and Characterization of
ADSCs. The ADSCs were plated in 6-well plates at a
concentration of 5 × 104 cells per well. The next day, the
cells were transduced with 20𝜇L of virus in the presence
of 8𝜇g/mL of Polybrene. After 48 hours, the cells were
transferred into T75 flasks at a density of 2 × 105 cells per
flask, and 5󸀠-azacytidine (Sigma-Aldrich) was added at a
final concentration of 10𝜇M for 96 hours with daily medium
changes. The reprogramming was immediately followed
by electroporation (BTX, Electro Square Porator ECM830,
Holliston, USA) with the pOKS2a plasmid [33]. The 5󸀠-
azacytidine-treated cells were detached and suspended
at a concentration of 5 × 105 cells in 50 𝜇L Spinner’s
modification of Eagle’s minimum essential medium (SMEM,
Life Technologies, Paisley, UK) with 8𝜇g of pOKS2a. The
electroporation machine was programmed to 12 pulses of 150
V and 150 𝜇s duration.
After 5 days, the cells were split 1 : 3, and 1mg/mL G418
was added to the medium for selection for 10 days; the
medium was replaced with fresh medium every 2 to 3 days.
For RT-PCR analysis, total RNA was extracted from
these cells using the RNeasy Mini kit (Qiagen, Hilden,
Germany), and cDNAwas synthesized using theHighCapac-
ity cDNA Reverse Transcription Kit (Applied Biosystems,
California, USA) following instructions provided by the
manufacturers.The following primers were used for RT-PCR:
MYH7, which codes for 𝛽MHC (GGCAAGACAGTGAC-
CGTGAAGandCGTAGCGATCCTTGAGGTTGTA);GJA1,
which codes for connexin 43 (AGGCGTGAGGAAAGTAC-
CAA and ACACCTTCCCTCCAGCAGTT);ATP2A2, which
codes for SERCA2a (GGTGCTGAAAATCTCCTTGC and
ATCAGTCATGCACAGGGTTG); GATA4, which codes for
the protein of the same name (GAGTAAACAAGAGCCTA-
GAGCCC and AGAAAACGACGGCAACAACG); MEF2C,
which codes for the protein of the same name (GAACAATC-
CCGGTGTGTCAGGA and CACCCAGTGGCAGCCTTT-
TACA); and GAPDH, which codes for glyceraldehyde 3-
phosphate dehydrogenase (ACCACAGTCCATGCCATCAC
and TCCACCACCCTGTTGCTGTA) (Bioneer, Alameda,
USA). The amplification conditions were 95∘C for 5min
4 BioMed Research International
neoR IRES GFPATP2A2
wPRERRE
cPPT cPPT
GJA1
NPPA
CMV
5
󳰀LTR 3󳰀LTR
Ψ
(a)
Electroporation
with pOKS2a
1
Day
Lentiviral 
transduction
2 3 4 5 10
G418 selection 
0
Plating of
transduced
ADSCs
Split of 
ADSC
RT-PCR and
immunocytochemistry
5
󳰀-aza
5
󳰀-aza
5
󳰀-aza
5
󳰀-aza
5
󳰀-aza
−2
reprogrammated
(b)
Figure 1: Lentiviral vectors and timeline of ADSC reprogramming. (a) Lentiviral vectors containing different cardiomyocyte-specific
promoters. LTR: long terminal repeat; RRE: Rev-responsive element; Ψ: packaging signal; ATP2A2/GJA1/NPPA/CMV : promoters; neoR:
G418 resistance gene; IRES: internal ribosome entry site; GFP: green fluorescent protein; cPPT: central polypurine tract; WPRE: Woodchuck
hepatitis virus posttranscription regulatory element. (b) Timeline of the ADSC reprogramming to the formation of CMPs. Lentiviral
transduction was performed with pLL-CNG, pLL-ANG, pLL-GNG, and pLL-NNG vectors. 5󸀠-aza: 5󸀠-azacytidine.
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Figure 2:GFP gene expression by different cell types transducedwith lentivectors containing cardiomyocyte-specific promoters. A lentivector
containing CMV promoter was used as a positive control. Cell images were acquired 48 hours after vector transduction.
followed by 35 cycles of 95∘C for 45 s, 45 s for exten-
sion [(ATP2A2)/51∘C; (GJA1)/54∘C; (GATA4)/55∘C; (MYH7,
GAPDH); 58.2∘C (Mef2c)] and 72∘C for 45 s, and finally 72∘C
for 7min (Mastercycler Gradient 5341, Eppendorf).
The RNA extracted from a human heart biopsy was
used as a positive control. The biopsy was acquired with the
consent of a patient undergoing cardiac surgery after approval
of the protocol by the ethics committee of UNIFESP (CEP-
UNIFESP 03/2810). RNA from ECV cell line was used as
a negative control. Total RNA was extracted using TRIzol
(Invitrogen) following instructions provided by themanufac-
turer. cDNA was synthesized using the High Capacity cDNA
Reverse Transcription Kit (Invitrogen).
In addition to RT-PCR, these cells were characterized
by immunocytochemistry using anti-desmin, anticardiac tro-
ponin T, antismooth muscle actin, and anti-von Willebrand
factor antibodies (Millipore MAB1693, Millipore MAB3430,
Dako M0851, and Dako A0082, resp.). The selected cells
were plated on coverslips placed in 24-well plates at 1 × 103
cells per well. After 48 hours, the medium was siphoned
off carefully, and the cells were fixed in cold acetone for 10
minutes at−20∘C,washedwith PBS, and blockedwith 50mM
NH
4
Cl, pH 8.0 solution for 15 minutes followed by washing
and blocking with PBS-10% BSA for 30 minutes. The cells
were washed again and incubated overnight at 4∘C with the
primary antibodies diluted 1 : 100 in PBS-1% BSA containing
0.01% Triton X-100, 0.01% Tween 20, and 0.01% gelatin. The
next day, the samples were washed and incubatedwith biotin-
labeled polyclonal rabbit anti-mouse IgG secondary antibody
(Dako, Glostrup, Denmark) diluted 1 : 100 in PBS for 1 hour
at room temperature in the dark. After washing with PBS,
the samples were incubated with Streptavidin Alexa Fluor
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Figure 3: GFP gene expression by different cell types transduced with lentivectors containing cardiomyocyte-specific promoters and selected
with G418. A lentivector containing CMV promoter was used as a positive control. Cell images were acquired 10 days after G418 selection.
594 Conjugate (Life Technologies, Grand Island, NY, USA)
diluted 1 : 500 in PBS for 1 hour at room temperature under
light protection. The samples were washed and incubated
with DAPI (Life Technologies, Eugene, OR, USA) diluted
1 : 1000 for 15 minutes at room temperature in the dark. The
coverslips were mounted with Fluoromount (Sigma-Aldrich,
Milwaukee, WI, USA) and analyzed using a BX51 fluorescent
microscope.
3. Results and Discussion
To identify and select CMPs to produce cardiomyocytes
in large numbers at a later stage, lentiviral vectors were
constructed containing an expression cassette with the GFP
and neoR genes under the control of cardiomyocyte-specific
promoters ATP2A2, GJA1, and NPPA (Figure 1). Because the
GFP and neoR genes were under the control of the same
cardiomyocyte-specific promoters, the green fluorescence
emitted by the transfected cells should indicate that these
cells were undergoing reprogramming into cardiomyocytes
and that they could be selected for G418 resistance for further
characterization, expansion, and terminal differentiation.
In this study, a vector with the CMV promoter, which
is a strong and constitutively active promoter [34], was
constructed using the same backbone as the previously
vectors as a control. The viral titer of this vector, named pLL-
CNG, using HEK293T cells was 2.3 × 108 TU/mL. HEK293T
cells, which are easy to culture and expand, have efficient
machinery for protein synthesis, which allows for high viral
and GFP production [35]. For this reason, this cell line has
been used as a standard cell line for lentiviral production and
viral titer determination [36].
To determine the viral titers of the vectors carrying
cardiomyocyte-specific promoters, we used the murine car-
diomyoblast cell line H9C2 because no GFP fluorescence
was seen using HEK293T cells, which is an important proof
of the specificity of these promoters. Viral titers were 7.9 ×
105 TU/mL, 2.6 × 105 TU/mL, 7 × 105 TU/mL, and 1.5 ×
105 TU/mL for pLL-CNG, pLL-ANG, pLL-GNG, and pLL-
NNG, respectively. The viral titers of pLL-CNG in H9C2
were three orders of magnitude lower than in HEK293T cells.
This result allows us to infer that viral vectors containing
cardiomyocyte-specific promoters should provide titers that
are three orders of magnitude higher in HEK293T cells than
the other cell types, and this magnitude of titer is typical in
this cell line [37].
pLL-derived vectors are pseudotyped with VSV-G,
which recognizes cell membrane phospholipids for self-
internalization [38] and allows for the transduction of a large
number of cell types efficiently. However, the vector titer also
depends on the promoter activity. The CMV promoter is a
well-known, constitutively active promoter, but its activity
varies among different cell types [37]. The viral titers of the
aftermentioned vectors were consistently the same order of
magnitude in our preparations (not shown), which demon-
strates the reproducibility of vector production.
To validate the cardiomyocyte specificity of the con-
structed vectors, these vectors were tested in cells from dif-
ferent tissues of origin: NIH3T3 from fibroblasts, HEK293T
from kidney, ADSCs from fat, and H9C2 from heart. As
discussed previously, HEK293T cells transduced with pLL-
CNG had many GFP-positive cells with strong fluorescence
intensity (Figure 2). The GFP-positive cells were also present
in H9C2, ADSC, and NIH3T3 cells transduced with pLL-
CNG, but the number of cells and the fluorescence intensity
were much lower than in HEK293T cells. On the other
hand, lentivectors constructed with cardiomyocyte-specific
promoters functioned only in H9C2 cells, and no GFP-
positive cells were found in HEK293T, NIH3T3, or ADSC
cells (Figure 2). The number of GFP-positive cells and the
fluorescence intensity were similar to the values observed
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Figure 4: Characterization of CMPs by immunocytochemistry and RT-PCR. (a) ADSCs transduced with lentivectors before G418 selection
(first column). These cells were selected with G418, expanded, and stained with anti-desmin (second column), anticardiac troponin T (third
column), antismooth muscle actin (fourth column), and anti-von Willebrand factor (fifth column) antibodies. The nontransduced ADSCs
were used as control (first line) and ECV304 cells were used as positive control for smooth muscle actin and von Willebrand factor staining.
(b) RT-PCR of the selected cells for the cardiomyocyte-specific genes. The GAPDH gene was used as control. The RNAs extracted from a
human heart and ECV were used as positive and negative controls, respectively.
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in cells transduced with pLL-CNG. Therefore, these vectors
were highly specific to cardiomyocytes.
Another goal of this work was to demonstrate that these
GFP-positive cells could be selected for G418 antibiotic
resistance for large-scale amplification at a later stage. The
H9C2 cells transduced with cardiomyocyte-specific vectors
were resistant to G418, and most of the selected cells, if not
all, were GFP positive (Figure 3). In contrast, the non-heart-
derived NIH3T3, HEK293T, and ADSC cells transduced
with cardiomyocyte-specific promoters did not survive in
the presence of G418. All cell types transduced with pLL-
CNG were resistant to G418 and positive for GFP. These
selected cells did not exhibit prolonged doubling times even
after a few months of observation (not shown). These results
demonstrate the specificity, selectivity, and expandability of
the G418-resistant cells.
Once the correct functioning of the cardiomyocyte-
specific vectors was verified, these vectors were tested in
ADSCs, which were conditioned to differentiate into car-
diomyocytes. A small population of ADSCs can differentiate
into cardiomyocytes when incubated with 5󸀠-azacytidine [11,
12, 14, 15]. To enforce this differentiation, we transfected these
cells with Yamanaka factors [8] soon after incubation with 5󸀠-
azacytidine (see Section 2). Approximately 0.007%, 0.009%,
and 0.004% of ADSCs were GFP positive after transduction
with pLL-ANG, pLL-GNG, and pLL-NNG, respectively.
Note that the percentages of GFP-positive cells that were
undergoing reprogramming to form cardiomyocytes were
very small. These numbers are much smaller than those seen
in the literature [11, 12, 14, 15]. None of the previous papers
used cardiomyocyte-specific promoters with a reporter gene
to monitor the reprogramming process, and most of them
evaluated some cardiomyocyte markers by immunocyto-
chemistry to validate the positivity of cardiomyocytes. As the
methods used to identify cardiomyocytes are different among
the different papers, a quantitative comparison is difficult;
however, the promoters used here are activated specifically
during different stages of cardiomyogenesis, so it is likely
that what we saw by GFP fluorescence were cardiomyocyte
precursor cells at different stages of differentiation, and this
fact can explain such low numbers of GFP-positive cells.
Finally, these GFP-positive ADSCs were selected for G418
resistance for expansion and further characterization. The
selected ADSCswere amplified in culture formonths without
variability in the doubling time, which indicates that these
cells are not completely differentiated into cardiomyocytes.
However, themorphology changed over time fromfibroblast-
like cells to flattened, cubic cells. These reprogrammed and
selected ADSCs were positive for troponin T (Figure 4(a)),
had flat and cuboid shapes, and contained intracellular
fibers, all characteristics of cardiomyocytes [39]. However,
the desmin staining pattern, as assessed by immunocyto-
chemistry, was notably different among the reprogrammed
cells (Figure 4(a)); specifically, the ADSCs modified with
pLL-GNG and pLL-NNG were positive for desmin, but the
pLL-ANG-modified cells were not. Unlike the labeling with
troponin T, the labeling with desmin showed a homogeneous
pattern across the whole cell area, without evidence of
fibers. None of the selected cells were positive for smooth
muscle actin, a typical marker for smooth cells, but they
were positive for von Willebrand factor, a typical marker
for endothelial cells, including the nondifferentiated ADSC.
The expression of von Willebrand factor in ADSC has not
been reported yet, but in hematopoietic mesenchymal stem
cells its expression was detected by RT-PCR [40]. Further
characterization of these cells by RT-PCR showed positivity
for five genetic markers of cardiomyocytes (Figure 4(b)).
These data indicate that the reprogrammed and selected
ADSCs had cardiomyocyte characteristics, albeit with sig-
nificant differences among them because these cells are still
undergoing the reprogramming process.
The RT-PCR results showed that the ADSCs were also
positive for most of the cardiomyocyte markers, except for
ATP2A2 (Figure 4(b)). ADSCs and cardiomyocytes share
several similarities [12–14, 41–43], suggesting that ADSCs
really do have the potential to differentiate into cardiomy-
ocytes. This fact implies that the number of cardiomyocytes
found after MSC differentiation in other studies might have
been overstated because some of the cardiomyocyte markers
detected might have been from the source and not the
differentiated cells. Consequently, the small numbers of GFP-
positive cells found in our study might be closer to the
real number of cardiomyocytes in these cultures than the
numbers found by others.
In conclusion, we demonstrated that lentivectors express-
ing GFP and neoR genes under the control of cardiomyocyte-
specific promoters can identify MSCs undergoing repro-
gramming into cardiomyocytes, and the CMPs can be
selected for G418 resistance for expansion and terminal
differentiation in cardiac cell-based therapies.
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